STCUBE
Biopharma and cosmetics distributor behind the BTN1A1-targeting immuno-oncology drug Nelmastobart and cosmetics brand Scenearth.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 1989 and listed on KOSDAQ in 2001, the company operates both a biopharma segment (immuno-oncology and antibody therapeutics) and a cosmetics distribution business. It holds the immuno-oncology drug Nelmastobart (BTN1A1-targeting, first-in-class) and its in-house cosmetics brand Scenearth. Current-period revenue is about 92% from cosmetics sales/distribution and 8% from industrial lens modules; Nelmastobart received its Phase 1 CSR in September 2024 and Phase 2 IND approval from Korea's MFDS in October 2025.
Products & technology
- ScenearthIn-house cosmetics brand
- industrial lens moduleDistributed to domestic companies
Clinical trials
data.go.kr4 MFDS clinical trial authorisations · 2022–2025 (Phase 1/2 2 · Phase 2 1 · Phase 1 1)
- Phase 2넬마스토바트2025-10-16
5 trial sites
- Phase 1/2넬마스토바트2025-03-20
5 trial sites
- Phase 1/2넬마스토바트2023-09-21
6 trial sites
- Phase 1넬마스토바트2022-03-15
2 trial sites
R&D and key agreements
Source: DART corporate disclosure넬마스토바트(Nelmastobart) · 고형암(소세포폐암→비소세포폐암 전환), 전이성 대장암 · 임상2상 IND 승인(2025.10) · First-in-class BTN1A1-targeting immuno-oncology drug; concurrent Korea/US Phase 1 approval in 2022; Phase 1 CSR received Sep 2024; Phase 1b/2 sponsor-initiated trial approved Mar 2025; Phase 2 IND approved for NSCLC Oct 2025
AI reads
MAA server logs · IP-verifiedSomeone asked an AI a question, and it fetched this page live to answer.
Collected for later use. Not a signal of interest.
- OpenAIChatGPT-Useranswer1
- OpenAIOAI-SearchBot3
- PerplexityPerplexityBot1
Measured since Aug 25, 2026 · 2 AI engines · last read Aug 26, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS.
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-14
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition